H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Mersana Therapeutics Inc (NASDAQ: MRSN) today and set a price target of $33. The company’s shares closed yesterday at $14.69.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.9% and a 48.6% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Jounce Therapeutics Inc.
Mersana Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $27.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $23.96 and a one-year low of $12.45. Currently, Mersana Therapeutics Inc has an average volume of 131.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
